Drug intelligence / Profile preview

PG-NSA

Development stage
Preclinical
Lead developer
WASEDA University
Modality
RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Topical
01

Overview

PG-NSA (Polyglycerol-based Nanostructured Organic Sheet) is a synthetic, two-dimensional nanomaterial designed as a therapeutic platform to treat radiation-induced mucositis. These nanosheets are functionalized with CD63-targeting aptamers, which allow them to selectively capture and sequester small extracellular vesicles (sEVs) released by damaged tissues. By removing these vesicles, which carry inflammatory triggers such as double-stranded DNA, PG-NSA prevents the activation of the STING (stimulator of interferon genes) pathway in macrophages, thereby suppressing excessive inflammation. Additionally, the polyglycerol structure of the nanosheet inherently scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS), providing a multi-modal anti-inflammatory effect. Its unique sheet-like geometry offers a significantly higher surface area and binding capacity for vesicles compared to traditional spherical nanoparticles.

Other names
Polyglycerol-based nanostructured organic sheetAptamer-functionalized polyglycerol nanostructured organic sheet
02

Targets

STING (Stimulator of interferon genes protein)CD63 (Lysosome-associated membrane glycoprotein 3)

Beyond the preview

Go deeper on PG-NSA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG-NSA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call